German construction sector still in recession, civil engineering only bright spot
HONG KONG/SHANGHAI - HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) will host a Research & Development update presentation in Shanghai and via webcast on October 31, 2025, the biopharmaceutical company announced Friday.
The event will feature Dr. Michael Shi, Executive Vice President, Head of R&D and Chief Medical Officer, who will present the company’s R&D strategy and vision. The presentation will include an overview of HUTCHMED’s Antibody Targeted Therapy Conjugates platform, highlighting its lead candidate HMPL-A251, along with updates on late-stage pipeline development.
The in-person event in Shanghai will run from 3:00 p.m. to 5:00 p.m. HKT and will be conducted in Chinese. A concurrent live webcast will be available. The in-person portion of the event is by invitation only.
An English-language webcast will be held later the same day at 8:00 p.m. HKT (8:00 a.m. EDT, 12:00 noon GMT) and is expected to last approximately one hour.
Both webcasts will be accessible through the company’s website, with replays available shortly after the event concludes.
HUTCHMED is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company currently has three medicines marketed in China, with one of these approved in multiple international markets including the US, Europe, and Japan.
The information was provided in a press release issued by the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.